View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 16, 2021updated 07 Jan 2022 8:43am

LumiraDx and Audere partner to improve access to Covid-19 tests

Laboratories using the SARS-CoV-2 RNA STAR Complete can integrate Audere’s HealthPulse@home into their systems.

LumiraDx Fast Lab Solutions, a LumiraDx business unit, has partnered with digital health non-profit Audere to improve access to Covid-19 tests.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The collaboration will enable LumiraDx to provide a self-collected Covid-19 nasal specimen collection kit authorised for use with its SARS-CoV-2 RNA STAR Complete assay to process self-collected samples.

This will allow laboratories using the SARS-CoV-2 RNA STAR Complete to integrate Audere’s HealthPulse@home Covid-19 specimen collection kit into their systems.

The laboratories can use HealthPulse@home authorised labelling instructions to offer their own self-collection Covid-19 specimen kits to the market.

Recently, Audere received Emergency Use Authorization (EUA) for its HealthPulse@home kit from the US Food and Drug Administration (FDA).

Audere chief operating officer Paul Isabelli said: “We are excited to partner with LumiraDx and further its mission to provide quality and highly accessible testing solutions that fit the needs of the LumiraDx Fast Lab Solutions network and the clinics and individuals it serves.

“The use of HealthPulse@home in conjunction with LumiraDx SARS-CoV-2 RNA STAR Complete will broaden access to self-testing solutions, allowing individuals to confidently continue on the path to normalcy.”

The LumiraDx SARS-CoV-2 RNA STAR Complete assay has received EUA from the FDA for use by authorised laboratories. It is only indicated for detecting nucleic acid from SARS-CoV-2, the disease that causes Covid-19.

LumiraDx Fast Lab Solutions president Sanjay Malkani said: “With the recent FDA EUA Intended Use expansion on the LumiraDx SARS-CoV-2 RNA STAR Complete, we are bringing access to innovative testing solutions right to the community – whether through high sensitivity mobile molecular labs or through the convenience of superior, simple, remote self-collection technologies with Audere.

“By working with Audere, and providing remote collection, we further enable high-quality, cost-effective, convenient and accurate testing that fits into the needs of the clinic and individuals.”

Earlier this year, India granted EUA for LumiraDx’s SARS-CoV-2 Antigen test.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network